Supplementary data: Progress of patients hospitalized with acute heart failure treated with empagliflozin

These are peer-reviewed supplementary materials for the article 'Progress of patients hospitalized with acute heart failure treated with empagliflozin' published in the Journal of Comparative Effectiveness Research.Supplementary table 1: Use of diuretics at admission and at initiation of treatment with empagliflozin.Supplementary table 2: Supplementary table 2. Characteristics of the sample according to initiation of empagliflozin with or without higher doses of furosemide than at admission.Aim: To describe the epidemiological, clinical and laboratory characteristics and clinical progress of patients hospitalized with heart failure (HF) who started treatment with empagliflozin before discharge. Methods: We performed a retrospective observational study of patients aged ≥18 years admitted to the Internal Medicine Department of University Hospital Jaen, Jaen, Spain with acute HF between 1May 2022 and 31 May 2023. Patients had to have a life expectancy of ≥1 year and have started treatment with empagliflozin during admission. Results: We included 112 patients (mean age, 85.2 ± 6.5 years; 67.9% women; 35.7 and 31.3% in NYHA functional classes III and IV; 73.2% with HF and preserved ejection fraction). Before admission, 80.4% were taking loop diuretics, 70.6% renin–angiotensin–aldosterone system inhibitors, 49.1% betablockers and 25% mineralocorticoid receptor antagonists. At admission, 94.6% were taking furosemide (15.2% at high doses, 36.6% at intermediate doses). The dose of furosemide was reduced at initiation of empagliflozin. At the end of follow-up, 13.4% of patients had died, 93.8% of the survivors continued treatment with empagliflozin and 26.8% had attended the emergency department with signs and symptoms of HF. Conclusion: Introduction of empagliflozin before discharge from hospital in patients admitted with HF made it possible to reduce the dose of diuretics during admission. The frequency of complications was as expected, and treatment was largely maintained.

本数据集为发表于《比较疗效研究杂志》的文章《接受恩格列净治疗的急性心力衰竭住院患者进展》的同行评审补充材料。补充表1：入院时和治疗开始时利尿剂的使用情况。补充表2：根据是否在入院时使用高于入院时的呋塞米剂量来启动恩格列净治疗，展示了样本的特征。研究目的：描述住院心力衰竭（HF）患者在接受恩格列净治疗前的流行病学、临床和实验室特征及临床进展。研究方法：我们对2022年5月1日至2023年5月31日期间被收入西班牙哈恩大学医院内科的、年龄≥18岁且患有急性HF的病人进行了回顾性观察研究。患者需有≥1年的预期寿命，并在入院期间开始接受恩格列净治疗。研究结果：我们纳入了112名患者（平均年龄，85.2 ± 6.5岁；女性占67.9%；在NYHA功能分级III和IV的分别占35.7%和31.3%；73.2%伴有心力衰竭和保持射血分数）。入院前，80.4%的患者正在使用袢利尿剂，70.6%使用肾素-血管紧张素-醛固酮系统抑制剂，49.1%使用β-受体阻滞剂，25%使用螺内酯受体拮抗剂。入院时，94.6%的患者正在使用呋塞米（其中15.2%为高剂量，36.6%为中剂量）。在启动恩格列净治疗时，呋塞米的剂量有所减少。在随访结束时，13.4%的患者已死亡，93.8%的存活者继续使用恩格列净治疗，26.8%的患者因心力衰竭的体征和症状前往急诊室。结论：对于入院心力衰竭患者，在出院前引入恩格列净治疗，有助于减少入院期间的利尿剂剂量。并发症的发生频率符合预期，治疗得到基本维持。